162 related articles for article (PubMed ID: 6372382)
1. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
[No Abstract] [Full Text] [Related]
2. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
Webster HK; Wiesmann WP; Pavia CS
Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
[No Abstract] [Full Text] [Related]
3. Exploiting biochemical differences in leukemia.
Coleman MS; Grever MR
Adv Exp Med Biol; 1984; 165 Pt B():315-20. PubMed ID: 6609538
[No Abstract] [Full Text] [Related]
4. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
[No Abstract] [Full Text] [Related]
5. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Mitchell BS; Koller CA; Kelley WN
Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
[No Abstract] [Full Text] [Related]
6. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Macdonald JS; Marsoni S; Bruno S; Poster D
Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
[TBL] [Abstract][Full Text] [Related]
7. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
Spiers AS; Parekh SJ
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
[No Abstract] [Full Text] [Related]
8. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Kefford RF; Fox RM
Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
[No Abstract] [Full Text] [Related]
9. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
Spiers AS
Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
[No Abstract] [Full Text] [Related]
10. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
11. Adenosine deaminase in malaria infected erythrocytes: unique parasite enzyme presents a new therapeutic target.
Wiesmann WP; Webster HK; Lambros C; Kelley WN; Daddona PE
Prog Clin Biol Res; 1984; 165():325-42. PubMed ID: 6334315
[No Abstract] [Full Text] [Related]
12. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
Agarwal RP
Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
[No Abstract] [Full Text] [Related]
13. Deoxycoformycin antagonizes ischemia-induced neuronal degeneration.
Phillis JW; O'Regan MH
Brain Res Bull; 1989 Mar; 22(3):537-40. PubMed ID: 2785431
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
[TBL] [Abstract][Full Text] [Related]
15. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
[TBL] [Abstract][Full Text] [Related]
16. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
17. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
18. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
19. Deoxycoformycin in the treatment of leukemias and lymphomas.
Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
[TBL] [Abstract][Full Text] [Related]
20. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]